A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...
Hyperkalemia is a condition where potassium levels in the blood are abnormally high. Anyone can develop it, but certain people, such as those with kidney dysfunction, have an increased risk. Having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results